×
About 465 results

ALLMedicine™ Primary Lateral Sclerosis Center

Research & Reviews  161 results

Segmental alterations of the corpus callosum in motor neuron disease: A DTI and texture...
https://doi.org/10.1016/j.nicl.2022.103061
NeuroImage. Clinical; Münch M, Müller HP et. al.

Jun 3rd, 2022 - Within the core neuroimaging signature of amyotrophic lateral sclerosis (ALS), the corpus callosum (CC) is increasingly recognized as a consistent feature. The aim of this study was to investigate the sensitivity and specificity of the microstruct...

Iron-sensitive MR imaging of the primary motor cortex to differentiate hereditary spast...
https://doi.org/10.1007/s00330-022-08865-6 10.1016/S1474-4422(19)30235-2 10.1007/s10072-020-04981-7 10.1007/s11910-021-01099-x 10.1007/s12311-016-0803-z 10.1111/j.1365-2990.2004.00587.x 10.1016/S1474-4422(08)70258-8 10.1136/jnnp.37.1.8 10.1016/0303-8467(92)90010-Z 10.1001/archneurpsyc.1956.02330200038005 10.1007/s004010000255 10.1212/WNL.55.1.89 10.1055/s-2001-15265 10.1136/jnnp.44.10.871 10.1001/archneurol.2009.19 10.3390/brainsci11050611 10.3174/ajnr.A2043 10.1016/j.expneurol.2011.12.024 10.1371/journal.pone.0035241 10.3174/ajnr.A4562 10.1016/j.nicl.2016.04.011 10.3174/ajnr.A5423 10.1016/j.nicl.2019.101934 10.1111/j.1468-1331.2010.02951.x 10.1016/S0140-6736(83)92879-9 10.1212/01.wnl.0000228242.53336.90 10.1136/jnnp-2019-322541 10.1080/146608200300079536 10.1016/S0022-510X(99)00210-5 10.2307/2529310 10.1080/14660820410021267 10.1212/01.wnl.0000200962.94777.71 10.3390/brainsci11050578 10.3390/brainsci11030403 10.1007/s00401-013-1115-8 10.1007/s00401-011-0916-x 10.1148/radiol.14141715 10.3389/fneur.2018.01117 10.1007/s00415-015-7791-7 10.1212/01.WNL.0000058901.75728.4E 10.1016/S1474-4422(11)70015-1 10.3174/ajnr.A2067 10.1093/brain/115.2.495 10.1007/s00401-003-0687-0 10.1007/s00401-007-0234-5 10.1001/archneur.1981.00510100058008 10.1111/j.1440-1789.1997.tb00042.x 10.1016/j.nicl.2017.10.024 10.1080/21678421.2020.1837173 10.1136/jnnp.2009.201103 10.1016/j.jns.2009.09.025 10.3389/fneur.2018.00981 10.1002/ana.20652 10.1001/jama.2014.14604 10.1186/1471-2350-14-118 10.1002/ana.25263 10.3389/fgene.2019.00434 10.1212/01.wnl.0000338530.77394.60 10.1002/ana.23641
European Radiology; Cosottini M, Donatelli G et. al.

May 21st, 2022 - Hereditary spastic paraplegia (HSP) is a group of genetic neurodegenerative diseases characterised by upper motor neuron (UMN) impairment of the lower limbs. The differential diagnosis with primary lateral sclerosis (PLS) and amyotrophic lateral s...

Acoustic Change Over Time in Spastic and/or Flaccid Dysarthria in Motor Neuron Diseases.
https://doi.org/10.1044/2022_JSLHR-21-00434
Journal of Speech, Language, and Hearing Research : JSLHR; Lévêque N, Slis A et. al.

Apr 13th, 2022 - This study aims to investigate acoustic change over time as biomarkers to differentiate among spastic-flaccid dysarthria associated with amyotrophic lateral sclerosis (ALS), spastic dysarthria associated with primary lateral sclerosis (PLS), flacc...

Use of Dalfampridine in Primary Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT02868567

Apr 7th, 2022 - This study will comprise an 18-week open label safety and tolerability trial. In this study, a total of 35 subjects with primary lateral sclerosis PLS or upper motor neuron predominate ALS will be enrolled. At the initial screening evaluation, a b...

Phenotype, Genotype and Biomarkers 2
https://clinicaltrials.gov/ct2/show/NCT04875416

Apr 7th, 2022 - The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progr...

see more →

Clinicaltrials.gov  18 results

Use of Dalfampridine in Primary Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT02868567

Apr 7th, 2022 - This study will comprise an 18-week open label safety and tolerability trial. In this study, a total of 35 subjects with primary lateral sclerosis PLS or upper motor neuron predominate ALS will be enrolled. At the initial screening evaluation, a b...

Phenotype, Genotype and Biomarkers 2
https://clinicaltrials.gov/ct2/show/NCT04875416

Apr 7th, 2022 - The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progr...

Imaging Biomarkers in ALS
https://clinicaltrials.gov/ct2/show/NCT02567136

Mar 15th, 2022 - The purpose of the study is to determine if we are able to find one or more biomarkers of Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS) using magnetic resonance imaging (MRI) scans at different levels, 3 tesla (3T) and 7 ...

HBPLS01 "Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis" HBPN01 "Individual Patient Expanded Access IND to Treat Polyneuropathy"
https://clinicaltrials.gov/ct2/show/NCT04825613

Feb 7th, 2022 - This is an Individual Patient Expanded Access IND with the primary goal of treatment for an individual with Primary Lateral Sclerosis. There are no FDA approved, fully restorative treatments for Primary Lateral Sclerosis. The subject will receive ...

Genomic Translation for Amyotrophic Lateral Sclerosis Care
https://clinicaltrials.gov/ct2/show/NCT02795897

Dec 29th, 2021 - In all patients, ALS/MND is caused by the progressive death of motor neurons. However, every patient is affected differently. Some develop symptoms in their 80's while others get sick in adolescence. Swallowing/speech are affected first in some pa...

see more →

News  6 results

New Compound Promising for ALS, Other Upper Motor Neuron Diseases
https://www.medscape.com/viewarticle/947056

Mar 11th, 2021 - NEW YORK (Reuters Health) - A new compound, NU-9, improved diseased upper motor neurons (UMN) in mice and shows promise for treating amyotrophic lateral sclerosis (ALS) in humans, though more work is needed before a clinical trial can be started, ...

Spasticity in MND Improved With Cannabinoid Oral Spray
https://www.medscape.com/viewarticle/906954

Dec 24th, 2018 - Nabiximols, a cannabinoid-based oral spray (Sativex, GW Pharmaceuticals) approved outside the United States for various multiple sclerosis (MS) symptoms, shows benefit in improving spasticity and pain in motor neuron disease when administered as a...

Motor neuron disease spasticity improved with cannabis-based oral spray, antispasticity drugs
https://www.mdedge.com/neurology/article/191256/neuromuscular-disorders/motor-neuron-disease-spasticity-improved-cannabis
Jeff Craven

Dec 14th, 2018 - Nabiximols, a cannabis-based oral spray containing delta-9 tetrahydrocannabinol and cannabidiol, significantly improved spasticity symptoms in combination with antispasticity drugs in patients with motor neuron disease in a randomized, double-blin.

Cannabis Extract Spray Reduces Spasticity in Patients With MND
https://www.staging.medscape.com/viewarticle/864049

May 31st, 2016 - COPENHAGEN — A cannabis extract reduces spasticity and is safe in patients with motor neuron diseases (MND), including amyotrophic lateral sclerosis (ALS), results of the phase 2 randomized multicenter CANALS trial suggest. A major symptom for pat...

Cannabis Extract Spray Reduces Spasticity in Patients With MND
https://www.medscape.com/viewarticle/864049

May 31st, 2016 - COPENHAGEN — A cannabis extract reduces spasticity and is safe in patients with motor neuron diseases (MND), including amyotrophic lateral sclerosis (ALS), results of the phase 2 randomized multicenter CANALS trial suggest. A major symptom for pat...

see more →

Patient Education  1 results see all →